DS
OVID icon

David Shaw’s Ovid Therapeutics OVID Stock Holding History

David Shaw’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.2K Buy
+36,877
New +$95.2K ﹤0.01% 4643
2024
Q2 		– Sell
-71,264
Closed -$217K – 4763
2024
Q1 		$217K Sell
71,264
-7,003
-9% -$23.4K ﹤0.01% 3892
2023
Q4 		$252K Sell
78,267
-6,041
-7% -$20.6K ﹤0.01% 3806
2023
Q3 		$324K Sell
84,308
-22,974
-21% -$82.6K ﹤0.01% 3590
2023
Q2 		$352K Sell
107,282
-231,878
-68% -$787K ﹤0.01% 3549
2023
Q1 		$875K Sell
339,160
-167,167
-33% -$396K ﹤0.01% 3247
2022
Q4 		$942K Sell
506,327
-184,996
-27% -$315K ﹤0.01% 3487
2022
Q3 		$1.27M Sell
691,323
-198,041
-22% -$414K ﹤0.01% 3407
2022
Q2 		$1.91M Buy
889,364
+663
+0.1% +$1.6K ﹤0.01% 3114
2022
Q1 		$2.79M Buy
888,701
+129,605
+17% +$408K ﹤0.01% 2978
2021
Q4 		$2.44M Buy
759,096
+30,166
+4% +$103K ﹤0.01% 3180
2021
Q3 		$2.45M Sell
728,930
-16,985
-2% -$61.9K ﹤0.01% 2844
2021
Q2 		$2.92M Buy
745,915
+160,210
+27% +$632K ﹤0.01% 2557
2021
Q1 		$2.35M Buy
585,705
+373,312
+176% +$1.24M ﹤0.01% 2458
2020
Q4 		$490K Buy
+212,393
New +$990K ﹤0.01% 3400

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

David Shaw's OVID Position: Q2 2026 in Review

David Shaw opened a new position in Ovid Therapeutics (OVID) in Q2 2026: 36,877 shares worth $99.2K. The stake represents ﹤0.01% of the portfolio and ranks #4643 among its holdings. This is a return to the name: David Shaw previously reported a position in OVID as recently as Q1 2024.

David Shaw first reported a position in OVID in Q4 2020 and has held it in 15 quarters since. The position peaked at $2.92M in Q2 2021. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • David Shaw held 36,877 shares of Ovid Therapeutics worth $99.2K as of Q2 2026.
  • Ovid Therapeutics was a new David Shaw position in Q2 2026.
  • Ovid Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4643 holding.
  • David Shaw first reported a position in Ovid Therapeutics in Q4 2020 and has held it in 15 quarters since.
  • David Shaw's Ovid Therapeutics position peaked at $2.92M in Q2 2021.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.